Antibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 27286-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- BCRP,ABCG2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated BCRP,ABCG2 antibody (Cat. #27286-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Long non-coding RNA DUXAP9 promotes hepatocellular carcinoma cell stemness via directly interacting with sox9.
Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
Repressing PDCD4 activates JNK/ABCG2 pathway to induce chemoresistance to fluorouracil in colorectal cancer cells.
Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms.
Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals.
Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells.
Preclinical Evaluation of the Novel Small-Molecule MSI-N1014 for Treating Drug-Resistant Colon Cancer via the LGR5/β-catenin/miR-142-3p Network and Reducing Cancer-Associated Fibroblast Transformation.
LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop.
Mangiferin promotes intestinal elimination of uric acid by modulating intestinal transporters.
1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
Dual actions of norathyriol as a new candidate hypouricaemic agent: uricosuric effects and xanthine oxidase inhibition.
Zeng R, Wang C, Wang W, Wang S
Environmental toxicology 2021 Sep;36(9):1793-1801
Environmental toxicology 2021 Sep;36(9):1793-1801
Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
Liu C, Pan Z, Chen Q, Chen Z, Liu W, Wu L, Jiang M, Lin W, Zhang Y, Lin W, Zhou R, Zhao L
Journal of experimental & clinical cancer research : CR 2021 Sep 22;40(1):297
Journal of experimental & clinical cancer research : CR 2021 Sep 22;40(1):297
Repressing PDCD4 activates JNK/ABCG2 pathway to induce chemoresistance to fluorouracil in colorectal cancer cells.
Hu L, Liang Y, Wu K, Wang C, Zhang T, Peng R, Zou F
Annals of translational medicine 2021 Jan;9(2):114
Annals of translational medicine 2021 Jan;9(2):114
Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms.
Zhao X, Wang J, Tang L, Li P, Ru J, Bai Y
Bioengineered 2021 Dec;12(1):589-600
Bioengineered 2021 Dec;12(1):589-600
Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Lin G, Yu Q, Xu L, Huang Z, Mai L, Jiang L, Su Z, Xie J, Li Y, Liu Y, Lin Z, Chen J
European journal of pharmacology 2021 Dec 5;912:174592
European journal of pharmacology 2021 Dec 5;912:174592
Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals.
Niu Y, Yang P, Li H, Li Q, Lin H, Gao L, Li L
Biological & pharmaceutical bulletin 2020 Nov 1;43(11):1653-1659
Biological & pharmaceutical bulletin 2020 Nov 1;43(11):1653-1659
Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells.
Tan Q, Lin S, Zeng Y, Yao M, Liu K, Yuan H, Liu C, Jiang G
Environmental toxicology 2020 Jun;35(6):643-651
Environmental toxicology 2020 Jun;35(6):643-651
Preclinical Evaluation of the Novel Small-Molecule MSI-N1014 for Treating Drug-Resistant Colon Cancer via the LGR5/β-catenin/miR-142-3p Network and Reducing Cancer-Associated Fibroblast Transformation.
Yadav VK, Huang YJ, George TA, Wei PL, Sumitra MR, Ho CL, Chang TH, Wu ATH, Huang HS
Cancers 2020 Jun 16;12(6)
Cancers 2020 Jun 16;12(6)
LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X, Guo S, Zhang Y, Zhao Y, Li X, Jia Y, Xu Y, Ma B
Cellular signalling 2020 Jan;65:109422
Cellular signalling 2020 Jan;65:109422
UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop.
Liu X, Ma F, Liu C, Zhu K, Li W, Xu Y, Li G, Niu Z, Liu J, Chen D, Li Z, Fu Y, Qian C
Cell death & disease 2020 Jan 6;11(1):10
Cell death & disease 2020 Jan 6;11(1):10
Mangiferin promotes intestinal elimination of uric acid by modulating intestinal transporters.
Li Q, Lin H, Niu Y, Liu Y, Wang Z, Song L, Gao L, Li L
European journal of pharmacology 2020 Dec 5;888:173490
European journal of pharmacology 2020 Dec 5;888:173490
1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
Jia Z, Zhang Y, Yan A, Wang M, Han Q, Wang K, Wang J, Qiao C, Pan Z, Chen C, Hu D, Ding X
Cell death & disease 2020 Aug 20;11(8):670
Cell death & disease 2020 Aug 20;11(8):670
Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
Guo J, Wang Q, Zhang Y, Sun W, Zhang S, Li Y, Wang J, Bao Y
Pharmacological research 2019 Sep;147:104387
Pharmacological research 2019 Sep;147:104387
Dual actions of norathyriol as a new candidate hypouricaemic agent: uricosuric effects and xanthine oxidase inhibition.
Lin H, Tu C, Niu Y, Li F, Yuan L, Li N, Xu A, Gao L, Li L
European journal of pharmacology 2019 Jun 15;853:371-380
European journal of pharmacology 2019 Jun 15;853:371-380
No comments: Submit comment
No validations: Submit validation data